For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of this treatment and Tafamidis meglumine represents a true breakthrough . These novel therapies stabilize the transthyretin protein, slowing its harmful build-up and lessening the impact of the disease . Patients are now reporting positive out